During a presentation at the American Academy of Dermatology Annual Meeting, Eric Simpson, M.D., M.C.R., reports results from a phase III study that found the monoclonal antibody dupilumab improved symptoms for trial participants with hand and foot atopic dermatitis, also known as eczema. Simpson says: “We are pleased to see such strong results in patients that experience intense itch and painful skin lesions on such critical areas of the body."

Sancy Leachman, M.D., Ph.D., says germline testing might be warranted after a patient has had three melanomas or has a family history of three first- and second-degree relatives having melanoma.

Alexandra Levin, M.P.H., was among the 165 fourth-year OHSU M.D. students who matched with residency programs on March 17. Levin, who was matched with the joint OHSU-Sky Lakes Cascades East Family Medicine Residency Program in Klamath Falls, says: “I’m thrilled to be going to a program that fits me so well and will train me to be a true, full-spectrum rural family physician. I’m feeling elation, joy, and excitement.”

An OHSU patient's car was stolen while she was recovering from surgery.

An OPB story discusses the alarming rates of depression, anxiety and suicidality, as well as increased demand for mental health care, in Oregon’s rural and coastal communities. Ajit Jetmalani, M.D., says: “People feel like things are completely chaotic and there’s no plan, but there really is a plan.”

Alexandra Levin, M.P.H., was among the 165 fourth-year OHSU M.D. students who matched with residency programs on March 17. Levin, who was matched with the joint OHSU-Sky Lakes Cascades East Family Medicine Residency Program in Klamath Falls, says: “I’m thrilled to be going to a program that fits me so well and will train me to be a true, full-spectrum rural family physician. I’m feeling elation, joy, and excitement”

OncLive interviews Chris Ryan, M.D., about data on the role of adjuvant pembrolizumab in treating renal cell carcinoma presented at the 2023 Genitourinary Cancers Symposium; Ryan says: “What we don’t know is if [giving] adjuvant treatment early on, as opposed to saving immunotherapy if a patient relapses with metastatic disease, will make a difference in overall survival [OS]. However, it is reasonable to consider adjuvant therapy and give benefit to the doubt that it may one day show improved OS, based on the compelling DFS benefit that we have seen.”

GenomeWeb reports on the Healthy Oregon Project team who presented at a recent American College of Medical Genetics meeting; Timothy O'Brien, Ph.D., said: "Overall, we have impacted more than 500 participants in Oregon by providing them with this health information to let them go on and take charge of their health and get recommendations and screening guidelines needed to manage their care.”

At the Third International Summit on Human Genome Editing in London, Shoukhrat Mitalipov, Ph.D., presents findings from his lab that showed that germline genome editing had resulted in unintended — and potentially dangerous — tweaks to the genomes of embryos, which standard DNA-reading tests used to screen embryos before implantation might not pick up.

The 25th million rider of the Tram is a 3-year-old boy receiving treatment for a brain tumor, called DIPG, at OHSU/Doernbecher.